Last reviewed · How we verify
Atacicept: with loading dose — Competitive Intelligence Brief
phase 2
B cell depleting agent
CD28/B7
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Atacicept: with loading dose (Atacicept: with loading dose) — EMD Serono. CD28/B7 costimulation blockade
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Atacicept: with loading dose TARGET | Atacicept: with loading dose | EMD Serono | phase 2 | B cell depleting agent | CD28/B7 | |
| RTX infusions | RTX infusions | Frédéric A. Houssiau, MD, PhD | phase 3 | Monoclonal antibody (B cell depleting agent) | CD20 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (B cell depleting agent class)
- EMD Serono · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Atacicept: with loading dose CI watch — RSS
- Atacicept: with loading dose CI watch — Atom
- Atacicept: with loading dose CI watch — JSON
- Atacicept: with loading dose alone — RSS
- Whole B cell depleting agent class — RSS
Cite this brief
Drug Landscape (2026). Atacicept: with loading dose — Competitive Intelligence Brief. https://druglandscape.com/ci/atacicept-with-loading-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing